BACKGROUND: We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays. METHODS: A total of 1520 patients who had advanced heart failure (New York Heart Association class III or IV) due to ischemic or nonischemic cardiomyopathies and a QRS interval of at least 120 msec were randomly assigned in a 1:2:2 ratio to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, beta-blockers, and spironolactone) alone or in combination with cardiac-resynchronization therapy with either a pacemaker or a pacemaker-defibrillator. The primary composite end point was the time to death from or hospitalization for any cause. RESULTS: As compared with optimal pharmacologic therapy alone, cardiac-resynchronization therapy with a pacemaker decreased the risk of the primary end point (hazard ratio, 0.81; P=0.014), as did cardiac-resynchronization therapy with a pacemaker-defibrillator (hazard ratio, 0.80; P=0.01). The risk of the combined end point of death from or hospitalization for heart failure was reduced by 34 percent in the pacemaker group (P<0.002) and by 40 percent in the pacemaker-defibrillator group (P<0.001 for the comparison with the pharmacologic-therapy group). A pacemaker reduced the risk of the secondary end point of death from any cause by 24 percent (P=0.059), and a pacemaker-defibrillator reduced the risk by 36 percent (P=0.003). CONCLUSIONS: In patients with advanced heart failure and a prolonged QRS interval, cardiac-resynchronization therapy decreases the combined risk of death from any cause or first hospitalization and, when combined with an implantable defibrillator, significantly reduces mortality. Copyright 2004 Massachusetts Medical Society
RCT Entities:
BACKGROUND: We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays. METHODS: A total of 1520 patients who had advanced heart failure (New York Heart Association class III or IV) due to ischemic or nonischemic cardiomyopathies and a QRS interval of at least 120 msec were randomly assigned in a 1:2:2 ratio to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, beta-blockers, and spironolactone) alone or in combination with cardiac-resynchronization therapy with either a pacemaker or a pacemaker-defibrillator. The primary composite end point was the time to death from or hospitalization for any cause. RESULTS: As compared with optimal pharmacologic therapy alone, cardiac-resynchronization therapy with a pacemaker decreased the risk of the primary end point (hazard ratio, 0.81; P=0.014), as did cardiac-resynchronization therapy with a pacemaker-defibrillator (hazard ratio, 0.80; P=0.01). The risk of the combined end point of death from or hospitalization for heart failure was reduced by 34 percent in the pacemaker group (P<0.002) and by 40 percent in the pacemaker-defibrillator group (P<0.001 for the comparison with the pharmacologic-therapy group). A pacemaker reduced the risk of the secondary end point of death from any cause by 24 percent (P=0.059), and a pacemaker-defibrillator reduced the risk by 36 percent (P=0.003). CONCLUSIONS: In patients with advanced heart failure and a prolonged QRS interval, cardiac-resynchronization therapy decreases the combined risk of death from any cause or first hospitalization and, when combined with an implantable defibrillator, significantly reduces mortality. Copyright 2004 Massachusetts Medical Society
Authors: Bryan C Wallace; Larry A Allen; Christopher E Knoepke; Russell E Glasgow; Carmen L Lewis; Diane L Fairclough; Laura J Helmkamp; Monica D Fitzgerald; Wendy S Tzou; Daniel B Kramer; Paul D Varosy; Sanjaya K Gupta; John M Mandrola; Scott C Brancato; Pamela N Peterson; Daniel D Matlock Journal: Am Heart J Date: 2020-04-20 Impact factor: 4.749
Authors: Khalid Chakir; Samantapudi K Daya; Takeshi Aiba; Richard S Tunin; Veronica L Dimaano; Theodore P Abraham; Kathryn M Jaques-Robinson; Kathryn Jacques; Edwin W Lai; Karel Pacak; Wei-Zhong Zhu; Rui-ping Xiao; Gordon F Tomaselli; David A Kass Journal: Circulation Date: 2009-02-23 Impact factor: 29.690
Authors: Robert M A van der Boon; Patrick Houthuizen; Rutger-Jan Nuis; Nicolas M van Mieghem; Frits Prinzen; Peter P T de Jaegere Journal: Curr Cardiol Rep Date: 2014-01 Impact factor: 2.931
Authors: Takeshi Aiba; Geoffrey G Hesketh; Andreas S Barth; Ting Liu; Samantapudi Daya; Khalid Chakir; Veronica Lea Dimaano; Theodore P Abraham; Brian O'Rourke; Fadi G Akar; David A Kass; Gordon F Tomaselli Journal: Circulation Date: 2009-02-23 Impact factor: 29.690
Authors: Gregory W Woo; Susan Petersen-Stejskal; James W Johnson; Jamie B Conti; Juan A Aranda; Anne B Curtis Journal: J Interv Card Electrophysiol Date: 2005-03 Impact factor: 1.900